← Back to Search

anti-IL-5/IL-5R therapy for Hypereosinophilic Syndrome

N/A
Recruiting
Research Sponsored by AstraZeneca
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 01 october 2020 - the most recent data available in 2023
Awards & highlights

Study Summary

The purpose of this study is to build the knowledge base on clinical characteristics, clinical management, and treatment outcomes of HES.

Eligible Conditions
  • Hypereosinophilic Syndrome

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~01 october 2020- the most recent data available in 2023
This trial's timeline: 3 weeks for screening, Varies for treatment, and 01 october 2020- the most recent data available in 2023 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Comorbidities prior to first HES record
Number of organ systems with HES signs and/or symptoms
Organ system with HES signs and/or symptoms
+1 more
Secondary outcome measures
Clinical outcomes
Demographic characteristics
HES and non-HES therapies & treatment pattern
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: other therapiesExperimental Treatment1 Intervention
Patients initiated other therapies.
Group II: anti-IL-5/IL-5R therapyExperimental Treatment1 Intervention
Patients initiated anti-IL-5/IL-5R therapy

Find a Location

Who is running the clinical trial?

AstraZenecaLead Sponsor
4,259 Previous Clinical Trials
288,593,652 Total Patients Enrolled
2 Trials studying Hypereosinophilic Syndrome
140 Patients Enrolled for Hypereosinophilic Syndrome

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
TrinetX Study of Hypereosinophilic Syndrome (HES) Without an Identifiable Non-haematological Secondary Cause
2023. "TrinetX Study of Hypereosinophilic Syndrome (HES) Without an Identifiable Non-haematological Secondary Cause". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06172751.
~0 spots leftby May 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top